Chylobinoid® is a patent pending mineral-infused, broad spectrum cannabinoid complex that is rich in CBDa. It provides more convenient, consistent dosing and greater potency than most products derived from hemp. Chylobinoid has properties similar to those of chylomicrons which are naturally produced lipoprotein particles that transport fats and cholesterol into the bloodstream through the lymphatic system.
Cannabidiolic Acid (CBDa)
Unlike most hemp-based products which consist primarily of CBD, Chylobinoid consists primarily of cannabidiolic acid (CBDa), the acid form of CBD. Although much of the research is preliminary, CBDa may be more effective than CBD with certain conditions. Moreover, Chylobinoid is designed to bypass the the first-pass hepatic metabolism, which contributes to the low bioavailability of CBD (around 8%). Avoiding the liver’s metabolic filter boosts bioavailability (from 8% to 60-80%) in addition to increasing tissue delivery and safety.
Chylobinoid consists of 75-85% magnesium-cannabidiolic acid (Mg-CBDa), approximately 5% cannabidiol (CBD), 5% other cannabinoids, and naturally occurring plant lipids. Because of its water-loving nature, Chylobinoid can be administered in an easy to swallow capsule form.
Chylobinoid contains substantially more CBDa than other hemp-derived products, since the application of heat and drying during conventional purification processes typically converts most CBDa contained within raw hemp to CBD. Recent research indicates that CBDa may have distinctive benefits and therefore be more effective than CBD with certain conditions such as epilepsy, anticipatory nausea, anxiety, pain and inflammation.
Specifically, CBDa appears to inhibit COX-2 (an enzyme that promotes inflammation), block GPR55 (G protein-coupled receptor 55), stimulate PPARG receptors (involved in neurodegenerative disorders), and stimulate 5-HT1A receptors (involved with controlling anxiety, addiction, appetite, sleep, pain perception, nausea and vomiting).